Company signals · Biotech & Pharma
Novartis AG
1 signal in the current window, with MitchelLake's leadership read on each.
Last updated
Market context: The wider read — a Talent Market Index of 111.2 (Hot), up 5.2 month-on-month — shows Americas signal flow rising (+6.3pts).
Novartis AG: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 24 tracked companies.
Signals at Novartis AG
MitchelLake in this thematic
More signals across Biotech & Pharma
Ma Activity · Americas
Biogen →Biogen announced and closed acquisition of Apellis Pharmaceuticals (immunology and rare diseases) in May 2026, and has just announced a second acquisition of an undisclosed company for $1 billion.
Capital Raising · Americas
BridgeBio →BridgeBio secured funding to support drug launch; United Airlines made an investment into the cell therapy space
Partnership · Americas
Basecamp Research →Basecamp Research integrated its EDEN antibiotic and vaccine design models into Claude Science, enabling scientists to design antibiotics and prioritize vaccine targets through Claude's interface.
Product Launch · Americas
Bota Biosciences →Bota Biosciences released Biology Protocol Language (BPL) and BPL-COGEN, a compiler-verified protocol language and generation pipeline for AI-driven biomanufacturing, announced on bioRxiv.
Product Launch · Americas
Neurocrine Biosciences →Neurocrine presented CRENESSITY clinical data at ENDO 2026 demonstrating hormone normalization in classic CAH and two-year cardiometabolic and bone health outcomes in adults.
Product Launch · Americas
Boehringer Ingelheim →Phase 3 trial data for obesity drug survodutide shows 19% discontinuation rate due to side effects, indicating potential safety/tolerability issues that may impact market launch strategy
Intelligence powered by Autonodal ↗